Tumor Biology

, Volume 36, Issue 11, pp 8405–8411 | Cite as

Overexpression of miR-100 inhibits growth of osteosarcoma through FGFR3

Research Article


Osteosarcoma (OS) is a prevalent, fast growing cancer. Identification of molecular regulation of OS growth may result in development of a novel therapy. Previous studies have highlighted a role of microRNAs (miRNAs) in the regulation of the carcinogenesis of OS, whereas the underlying mechanisms are not completely understood. Moreover, a role of miR-100 in the growth control of OS is not clear. Here we reported significantly higher levels of fibroblast growth factor receptor 3 (FGFR3) and significantly lower levels of miR-100 in the OS specimen, compared to those in the paired normal bone tissues. Bioinformatics analysis and luciferase reporter assay suggest that miR-100 binds to the 3′UTR of FGFR3 mRNA to prevent its translation. To prove it, we modified miR-100 levels in OS cells. We found that overexpression of miR-100 in OS cells decreased FGFR3 protein levels, whereas inhibition of miR-100 increased FGFR3 protein levels, without affecting FGFR3 transcripts. Moreover, overexpression of miR-100 suppressed the OS growth in vitro and in vivo, while inhibition of miR-100 significantly increased OS growth. Taken together, our data demonstrate that miR-100 may inhibit the growth of OS through FGFR3.


Osteosarcoma (OS) Fibroblast growth factor receptor 3 (FGFR3) miR-100 


Conflicts of interest



  1. 1.
    Tsuchiya H, Tomita K, Mori Y, Asada N, Morinaga T, Kitano S, et al. Caffeine-assisted chemotherapy and minimized tumor excision for nonmetastatic osteosarcoma. Anticancer Res. 1998;18:657–66.PubMedGoogle Scholar
  2. 2.
    Yang J, Zhang W. New molecular insights into osteosarcoma targeted therapy. Curr Opin Oncol. 2013;25:398–406.CrossRefPubMedGoogle Scholar
  3. 3.
    Li G, Fu D, Liang W, Fan L, Chen K, Shan L, et al. Cyc1 silencing sensitizes osteosarcoma cells to trail-induced apoptosis. Cell Physiol Biochem. 2014;34:2070–80.CrossRefPubMedGoogle Scholar
  4. 4.
    Liu Y, He J, Chen X, Li J, Shen M, Yu W, et al. The proapoptotic effect of formononetin in human osteosarcoma cells: involvement of inactivation of erk and akt pathways. Cell Physiol Biochem. 2014;34:637–45.CrossRefPubMedGoogle Scholar
  5. 5.
    Wang Q, Cai J, Wang J, Xiong C, Zhao J. Mir-143 inhibits egfr-signaling-dependent osteosarcoma invasion. Tumour Biol. 2014;35:12743–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Xiao Q, Zhang X, Wu Y, Yang Y. Inhibition of macrophage polarization prohibits growth of human osteosarcoma. Tumour Biol. 2014;35:7611–6.CrossRefPubMedGoogle Scholar
  7. 7.
    Ponten J, Saksela E. Two established in vitro cell lines from human mesenchymal tumours. Int J Cancer. 1967;2:434–47.CrossRefPubMedGoogle Scholar
  8. 8.
    Sicard F, Gayral M, Lulka H, Buscail L, Cordelier P. Targeting mir-21 for the therapy of pancreatic cancer. Mol Ther. 2013;21:986–94.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Tavano F, di Mola FF, Piepoli A, Panza A, Copetti M, Burbaci FP, et al. Changes in mir-143 and mir-21 expression and clinicopathological correlations in pancreatic cancers. Pancreas. 2012;41:1280–4.CrossRefPubMedGoogle Scholar
  10. 10.
    Ali S, Ahmad A, Banerjee S, Padhye S, Dominiak K, Schaffert JM, et al. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of mir-200 and mir-21 expression by curcumin or its analogue cdf. Cancer Res. 2010;70:3606–17.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Luo XJ, Tang DG, Gao TL, Zhang YL, Wang M, Quan ZX, et al. MicroRNA-212 inhibits osteosarcoma cells proliferation and invasion by down-regulation of Sox4. Cell Physiol Biochem. 2014;34:2180–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Li F, Li S, Cheng T. Tgf-beta1 promotes osteosarcoma cell migration and invasion through the mir-143-versican pathway. Cell Physiol Biochem. 2014;34:2169–79.CrossRefPubMedGoogle Scholar
  13. 13.
    Xu H, Liu X, Zhao J. Down-regulation of mir-3928 promoted osteosarcoma growth. Cell Physiol Biochem. 2014;33:1547–56.CrossRefPubMedGoogle Scholar
  14. 14.
    Xu G, Wang J, Jia Y, Shen F, Han W, Kang Y. MiR-142-3p functions as a potential tumor suppressor in human osteosarcoma by targeting HMGA1. Cell Physiol Biochem. 2014;33:1329–39.CrossRefPubMedGoogle Scholar
  15. 15.
    Pan W, Wang H, Jianwei R, Ye Z. MicroRNA-27a promotes proliferation, migration and invasion by targeting MAP2k4 in human osteosarcoma cells. Cell Physiol Biochem. 2014;33:402–12.CrossRefPubMedGoogle Scholar
  16. 16.
    Friesel R, Maciag T. Fibroblast growth factor prototype release and fibroblast growth factor receptor signaling. Thromb Haemost. 1999;82:748–54.PubMedGoogle Scholar
  17. 17.
    Jaye M, Schlessinger J, Dionne CA. Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction. Biochim Biophys Acta. 1992;1135:185–99.CrossRefPubMedGoogle Scholar
  18. 18.
    Wang X, Cao X. Regulation of metastasis of pediatric multiple myeloma by MMP13. Tumour Biol. 2014.Google Scholar
  19. 19.
    Fujimoto J, Hori M, Ichigo S, Tamaya T. Expressions of the fibroblast growth factor family (FGF-1, -2 and -4) mRNA in endometrial cancers. Tumour Biol. 1996;17:226–33.CrossRefPubMedGoogle Scholar
  20. 20.
    Soundararajan P, Fawcett JP, Rafuse VF. Guidance of postural motoneurons requires MAPK/ERK signaling downstream of fibroblast growth factor receptor 1. J Neurosci. 2010;30:6595–606.CrossRefPubMedGoogle Scholar
  21. 21.
    Kuslak SL, Marker PC. Fibroblast growth factor receptor signaling through MEK-ERK is required for prostate bud induction. Differentiation. 2007;75:638–51.CrossRefPubMedGoogle Scholar
  22. 22.
    Williamson AJ, Dibling BC, Boyne JR, Selby P, Burchill SA. Basic fibroblast growth factor-induced cell death is effected through sustained activation of p38MAPK and up-regulation of the death receptor p75ntr. J Biol Chem. 2004;279:47912–28.CrossRefPubMedGoogle Scholar
  23. 23.
    Ren T, Qing Y, Dai N, Li M, Qian C, Yang Y, et al. Apurinic/apyrimidinic endonuclease 1 induced upregulation of fibroblast growth factor 2 and its receptor 3 induces angiogenesis in human osteosarcoma cells. Cancer Sci. 2014;105:186–94.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Mirabello L, Yu K, Berndt SI, Burdett L, Wang Z, Chowdhury S, et al. National osteosarcoma etiology study G: a comprehensive candidate gene approach identifies genetic variation associated with osteosarcoma. BMC Cancer. 2011;11:209.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Jang JH. Identification and characterization of soluble isoform of fibroblast growth factor receptor 3 in human SaOS-2 osteosarcoma cells. Biochem Biophys Res Commun. 2002;292:378–82.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of OrthopedicsThe First Affiliated Hospital of Liaoning Medical UniversityJinzhouChina
  2. 2.Department of OncologyThe First Affiliated Hospital of Liaoning Medical UniversityJinzhouChina

Personalised recommendations